BI Asset Management Fondsmaeglerselskab A S Sells 6,475 Shares of Abbott Laboratories $ABT

BI Asset Management Fondsmaeglerselskab A S lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,498 shares of the healthcare product maker’s stock after selling 6,475 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Abbott Laboratories were worth $11,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Harbor Capital Advisors Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $27,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at about $33,000. Leonteq Securities AG bought a new position in Abbott Laboratories in the 4th quarter valued at about $35,000. Finally, Board of the Pension Protection Fund bought a new position in Abbott Laboratories in the 4th quarter valued at about $38,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.5%

NYSE:ABT opened at $91.20 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $158.85 billion, a price-to-earnings ratio of 25.55, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The firm has a 50-day moving average price of $92.80 and a two-hundred day moving average price of $109.31.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Weiss Ratings cut shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research report on Monday, April 27th. Finally, Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.